GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf018 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Qin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: DNA (Cytosine-5-)-Methyltransferases, Lung Neoplasms, DNA (Cytosine-5-)-Methyltransferase 1, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NLM NIH HHS.
Abstract (Originalsprache)
DNA methylation alterations, including hypermethylation and silencing of tumor suppressor genes, contribute to cancer formation and progression. The FDA-approved nucleoside analogs azacytidine and decitabine are effective demethylating agents for hematologic malignancies but their general use has been limited by their toxicity and ineffectiveness against solid tumors. GSK-3484862, a dicyanopyridine-containing, DNMT1-selective inhibitor and degrader, offers a promising lead for developing novel demethylating therapeutics. Here, we demonstrate that GSK-3484862 treatment upregulates DNMT3B expression in lung cancer cell lines (A549 and NCI-H1299). Disrupting DNMT3B in NCI-H1299 sensitizes these cells to GSK-3484862, enhancing its inhibitory effects on cell viability and growth. GSK-3484862 treatment induces demethylation at DNMT3B regulatory elements including a candidate enhancer located ∼10 kb upstream of the DNMT3B transcription start site, as well as at the promoter of TERT (telomerase reverse transcriptase), a potential activator of DNMT3B expression. These demethylation events correlate with upregulation of DNMT3B expression. These findings suggest that combining inhibitors targeting DNMT1, the maintenance methyltransferase, with those targeting DNMT3A/3B, the de novo methyltransferases, or using pan-DNMT inhibitors, could enhance anticancer efficacy and reduce resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
- New England Biolabs, Inc., Ipswich, MA 01938, United States.
ORCID-Profile: Ivan R Corrêa, Xiaodong Cheng
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NLM NIH HHS
- National Institutes of Health
- Cancer Prevention and Research Institute of Texas
- National Library of Medicine Training Program in Biomedical Informatics and Data Science
- Texas Tobacco Settlement–Molecular Mechanisms of Tobacco Carcinogenesis
- CPRIT Scholars in Cancer Research
Zitieren
APA
Chen, Q., Hardikar, S., Kondo, K., Dai, N., Corrêa, I. R., Yu, M., Estecio, M. R., Zhang, X., Chen, T., & Cheng, X. (2025). GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells. NAR Cancer. https://doi.org/10.1093/narcan/zcaf018
Vancouver
Chen Q, Hardikar S, Kondo K, Dai N, Corrêa IR, Yu M, et al. GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells. NAR Cancer. 2025. doi:10.1093/narcan/zcaf018
BibTeX
@article{Chen2025,
author = {Chen, Qin and Hardikar, Swanand and Kondo, Kimie and Dai, Nan and Corrêa, Ivan R and Yu, Meigen and Estecio, Marcos R and Zhang, Xing and Chen, Taiping and Cheng, Xiaodong},
title = {GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf018}
}
EUVIMED